Background:
@EN We have already shown that a new vitamin D3 analogue, calcipotriol, is a potent growth inhibitor for human keratinocytes, indicating the close relationship between the in vitro inhibitory effect of calcipotriold and it's therapeutic
effectiveness
for psoriasis.
@ES Objective:
@EN Our purpose was to evaluate the evaluate the clinical efficacy, safety and tolerability of calcipotriol (50μg/g) ointment twice daily in the treatment of psoriasis.
@ES Methods:
@EN We treated 31 patients with calcipotriol for 6 weeks. Patients were provided with a maximum of 100g of ointment per weeks. Efficacy, as measured by the Psoriasis Area and Severity Index(PASI), and safety were assessed at 2, 4, and 6 weeks.
@ES Results:
@EN Reduction of PASI was statistically significant at all time points for treatments (p<0.01). At the completion of 6 weeks of treatment, the mean PASI reduction was 3.61. An analysis of patients overall self-assessment at 6 weeks showed
clearance
or
marked improvement in 61%. Some patients developed minimal irritation of lesional or perilesional skin(6.5%). Laboratory tests did not show any significant changes ; in particular there was no change in serum calcium levels.
@ES Conclusion:
@EN Calcipotriol ointment was effective as measured by the PASI and the self-assessment in patients with psoriasis. This treatment was well tolerated. (Kor J Dermatol 1993 ; 31 (2) : 217-223)
|